Changing the Course
of Cardiovascular Disease

Advancing groundbreaking clinical programs to address the continuing unmet needs of patients with cardiovascular disease.

ABOUT US

We translate our world-class expertise in cardiovascular signaling pathways into groundbreaking therapeutics for patients.

Acquire assets where we have unique insights into their use in cardiovascular disease

Discover new targets and novel drug candidates

Innovate by advancing programs targeting novel CV biology into late-stage development

A Next Generation Cardiovascular Company

We are addressing the continuing unmet needs of patients with cardiovascular disease through:

Groundbreaking clinical programs in PDE9 and CaMKII inhibition

Experienced team of cardiovascular experts and industry veterans with track records of success

Strategic portfolio approach driven by an in-house drug discovery group and a highly experienced search and evaluation team

Foundational partnerships with key strategics and investors

Our Pipeline

We are advancing
Groundbreaking Clinical Programs
across multiple cardiovascular diseases

Addressing the unmet needs that remain with heart failure

Our novel mechanisms have the potential to improve the multi-drug standard of care for heart failure.

Our PDE9 inhibitor is in Phase 2 and targets an enzyme that is elevated in all forms of heart failure. Learn more about PDE9.

We are the first to advance a CaMKII inhibitor into the clinic, targeting an enzyme that disrupts calcium signaling, a long-recognized driver of heart disease. Learn more about CaMKII.

Taking on the challenge of cardiac arrhythmias

With its role in calcium handling, Cardurion’s CaMKII inhibitor has the potential to treat cardiac arrhythmias regardless of origin. Arrhythmias range from common diseases acquired through aging, such as atrial fibrillation (AFib), to rare genetic arrythmias.

Cardurion is currently conducting a clinical trial with its CaMKII inhibitor in the treatment of a catecholaminergic polymorphic ventricular tachycardia (CPVT), rare genetic arrhythmia with a significant mortality rate. Learn more about CaMKII.